|Publisher||Public Library of Science (PLoS)|
Both proteomic TB risk signatures predicted progression to incident TB within a year of diagnosis. To our knowledge, these are the first validated prognostic proteomic signatures. Neither meet the minimum criteria as defined in the WHO Target Product Profile for a progression test. More work is required to develop such a test for practical identification of individuals for investigation of incipient, subclinical, or active TB disease for appropriate treatment and care.
Known Files and URLs
|application/pdf 2.3 MB ||
|application/pdf 2.4 MB ||
grouping other versions (eg, pre-print) and variants of this release